We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Genetic Risk Score Identifies Type 1 Diabetes in MODY Testing

By LabMedica International staff writers
Posted on 20 Aug 2026

Accurately distinguishing maturity-onset diabetes of the young from type 1 diabetes is difficult in routine care, especially when onset occurs in adolescence or early adulthood. More...

Although maturity-onset diabetes of the young (MODY) typically results from a single gene change and is often suspected in patients diagnosed before age 25, most referrals return negative results, leaving the cause uncertain. This diagnostic gray zone can delay tailored management and prompt additional testing. New findings demonstrate that adding a type 1 diabetes genetic risk score to standard MODY workflows can uncover otherwise hidden type 1 cases.

At the University of Exeter, investigators evaluated a type 1 genetic risk score—developed at Exeter—for use alongside routine MODY gene panel testing. The score is introduced as a cheap, simple tool that considers all known genetic risk factors for type 1 diabetes. Applied after a negative MODY result, it is intended to provide an additional route to diagnosis within existing laboratory pathways.

In a study of more than 1,100 insulin-treated individuals referred for MODY testing, approximately 80% received a negative genetic result with no clear explanation. Among those with negative results, the score indicated that 16%—around 180 people—had atypical type 1 diabetes. Incorporating the score into routine testing could enable genetic laboratories to issue a type 1 diabetes diagnosis for patients who previously would have received no explanation, and the approach will now be adopted as part of NHS testing.

The work was published in Diabetes Care on August 18, 2026. The study and clinical translation were supported by the Exeter Genomics Laboratory at the Royal Devon University Healthcare NHS Foundation Trust. Additional clinical perspectives were provided by Gloucestershire Hospitals NHS Foundation Trust and Diabetes UK.

“In clinic, it’s extremely challenging to distinguish between MODY and type 1 diabetes, yet getting the right diagnosis is crucial to getting the right treatment. We found that applying the type 1 genetic risk score to patients who tested negative for MODY is effective in identifying patients with type 1 diabetes, reducing the need for expensive further testing and providing answers to patients,” said Kashyap Patel, associate professor at the University of Exeter and consultant physician in diabetes and endocrinology.

Related Links
University of Exeter


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Pipette Calibration System
Artel PCS®
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Longitudinal Heart Stress Assessment Improves Prediction of Cardiovascular Outcomes

Accurately predicting cardiovascular disease (CVD) risk in older adults is challenging when assessments rely on single, point-in-time biomarker measurements. Dynamic indicators that reflect evolving cardiac... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.